An artificial intelligence (AI) model developed by Mayo Clinic and Ultromics, Ltd., an AI echocardiography company based in Oxford, England, is highly accurate in screening for cardiac amyloidosis, a rare and progressive type of heart failure, according to a new study. The model is the first and only AI tool of its kind.

A new skin-like sensor developed by an international team led by researchers at Penn State could help doctors monitor vital signs more accurately, track healing after surgery and even help patients with bladder control issues.

A new study by researchers at the Icahn School of Medicine at Mount Sinai, Memorial Sloan Kettering Cancer Center, and collaborators, suggests that artificial intelligence (AI) could significantly improve how doctors determine the best treatment for cancer patients—by enhancing how tumor samples are analyzed in the lab.

Researchers from DZNE, Ludwig-Maximilians-Universität München (LMU), and Technical University of Munich (TUM) have found that the enzyme “gamma-secretase”—implicated in Alzheimer’s disease and cancer—selects its reaction partners according to a complex scheme of molecular features.

Revolutionary Implant Integrates Sensor-Driven Technology and Cloud Connectivity to Enhance Hearing Outcomes and Patient Monitoring

Innovative Device Enhances Ease, Precision, and Accessibility for Patients Using Preservative-Free Eye Medications

InspireMD (Nasdaq:NSPR) announced today that it launched its CGuard Prime carotid stent in the U.S. after receiving FDA premarket approval (PMA) last month.

NEUCHÂTEL, Switzerland, July 9, 2025 /PRNewswire/ — Aktiia, a pioneer in optical blood pressure monitoring, announced today that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for over-the-counter (OTC) use of its cuffless blood pressure monitoring technology.

GAINESVILLE, Fla., July 9, 2025 /PRNewswire/ — Exactech, a global medical technology leader, announced the Equinoxe® Scapula Reconstruction System for acromial and scapular spine fractures has received 510(k) clearance1 from the U.S. Food and Drug Administration, marking a significant advancement in the treatment of acromial and scapular spine fractures.

The new implant carries a reservoir of glucagon that can be stored under the skin and deployed during an emergency — with no injections needed.